Can a new injection stop the wasting of cancer cachexia?

NCT ID NCT07735104

Not yet recruiting Symptom relief Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called QLS2319 for cancer cachexia — the severe weight loss and muscle wasting that can happen with advanced cancer. The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with cancer cachexia to see if it is safe and might help. The goal is to gather initial information on whether this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called QLS2319, given as a shot under the skin
What this could lead to: If it works, this could point toward a treatment for the severe weight loss and muscle wasting that often accompanies advanced cancer.
What could go wrong: This is an early-phase trial, so the drug may not prove safe or effective. Side effects are unknown, and results in healthy volunteers may not predict outcomes in cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

paraneoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CACHEXIA CANCER CACHEXIA SYNDROME

Contacts and locations

Locations

Sun-Yat-sen University Cancer Center

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.